PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / March 23, 2017 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, today announces that the Company will file its financial results for the three and 12 months ended December 31, 2016 with the U.S. Securities and Exchange Commission ("SEC") before the opening of the U.S. financial markets on March 30, 2017. The Form 20F will include audited consolidated financial statements, as well as additional information regarding the Company. The Form 20F will be available at www.sec.gov and at www.rosettagenomics.com.
Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, and Ron Kalfus, Chief Financial Officer of Rosetta Genomics, will host a conference call on Thursday, March 30, 2017 at 10:00 a.m. Eastern time to provide an update on the Company's business and respond to questions.
Individuals interested in listening to the conference call may do so by dialing (866) 239-5859, or for international callers (702) 495-1913. The conference ID number is 92837292. The call will be available through webcast, which can be accessed on the investor relations section of the Company's website at www.rosettagx.com.
A telephone replay will be available through April 5, 2017 by dialing (855) 859-2056 or for international callers (404) 537-3406, and entering the Conference ID number 92837292. The webcast will be available on the Company's website for 30 days following the completion of the call.
About Rosetta Genomics
Rosetta is pioneering the field of molecular diagnostics by offering rapid and accurate diagnostic information that enables physicians to make more timely and informed treatment decisions to improve patient care. Rosetta has developed a portfolio of unique diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists and other specialists to help them deliver better care to their patients. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of cancer in thyroid nodules, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company's Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
Rosetta Genomics Contact:
Ken Berlin, President & CEO
(267) 298-1159
[email protected]
Rosetta Genomics Investor Contact:
LHA
Anne Marie Fields
(212) 838-3777
[email protected]
SOURCE: Rosetta Genomics Ltd.